Core Viewpoint - Abbott Laboratories plans to acquire Exact Sciences Corp. for approximately $21 billion, offering $105 per share to shareholders, with the acquisition expected to be completed in the second quarter of the following year [1][5]. Company Performance - Exact Sciences reported $851 million in revenue for the third quarter and has increased its full-year revenue forecast to between $3.22 billion and $3.235 billion, indicating strong financial performance and growth potential [3][5]. - The stock of Exact Sciences is currently trading at $101.29, reflecting a slight decrease of 0.16%, with a market capitalization of approximately $19.19 billion [4]. Market Context - The U.S. market for cancer screening and precision oncology diagnostics is valued at around $60 billion, highlighting significant growth opportunities in this sector [3]. - Following the acquisition announcement, Exact Sciences shares soared by 17%, indicating positive market sentiment [2]. Analyst Insights - Stifel Nicolaus set a price target of $105 for Exact Sciences, aligning with Abbott's acquisition offer, suggesting a potential upside of about 3.66% from the stock's price at the time of the report [2][5].